|
BM |
PB |
CB |
Mode of collection |
Usually in operation theatre, under general anesthesia, puncture of spinailiaca posterior, aspiration of up to 20 ml/kg body weight BM containing blood (corresponding to maximal 1500 ml or 25% of blood volume in children) anticoagulated with Citrate and / or heparin |
Mobilization of progenitor cells from bone marrow with eg; G-CSF pretreatment, apheresis of mononuclear cells into citrate anticoagulant |
After completed birth collection of blood from umbilical cord into citrate anticoagulant |
Typical processing steps |
Removal of larger particulate matter by filtration, depending on ABO compatibility plasma or red cell reduction;
Selection and/or depletion of cells according to CD markers |
If needed volume reduction; selection and/or depletion of cells according to CD markers |
Depletion of red cells, volume reduction |
Storage |
Liquid storage after collection up to 72h at 2 to 6°C, or up to 48h at room temperature, or freezing within 72h after collection in a suitable cryoprotectant (e.g. 10% DMSO):≤‑140°C (above or in liquid nitrogen) several years as validated |
Liquid storage after collection up to 72h at 2 to 6°C, or up to 48h at room temperature, or freezing within 72h after collection in a suitable cryoprotectant (e.g. 10%DMSO): ≤‑140°C (above or in liquid nitrogen) several years as validated |
Freezing within 48h in a suitable cryopreservative solution (e.g. 10% DMSO): ≤‑140°C (above or in liquid nitrogen) several years as validated |
Dose rate autologous |
≥2 x 108 nucleated cells/kg body weight |
≥2 x 106 CD34+CD45+ cells/kg body weight |
≥1.5 x 107 nucleated or CD45+cells/kg body weight |
Dose rate allogeneic |
≥2 x 108 nucleated cells/kg body weight |
≥4 x 106 CD34+CD45+cells/kg body weight |
≥3 x 107 nucleated or CD45+cells/kg body weight |